Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;157(12):1425-1436.
doi: 10.1001/jamadermatol.2021.3884.

Association Between Melanoma Detected During Routine Skin Checks and Mortality

Affiliations

Association Between Melanoma Detected During Routine Skin Checks and Mortality

Caroline G Watts et al. JAMA Dermatol. .

Abstract

Importance: Early melanoma diagnosis is associated with better health outcomes, but there is insufficient evidence that screening, such as having routine skin checks, reduces mortality.

Objective: To assess melanoma-specific and all-cause mortality associated with melanomas detected through routine skin checks, incidentally or patient detected. A secondary aim was to examine patient, sociodemographic, and clinicopathologic factors associated with different modes of melanoma detection.

Design, setting, and participants: This prospective, population-based, cohort study included patients in New South Wales, Australia, who were diagnosed with melanoma over 1 year from October 23, 2006, to October 22, 2007, in the Melanoma Patterns of Care Study and followed up until 2018 (mean [SD] length of follow-up, 11.9 [0.3] years) by using linked mortality and cancer registry data. All patients who had invasive melanomas recorded at the cancer registry were eligible for the study, but the number of in situ melanomas was capped. The treating doctors recorded details of melanoma detection and patient and clinical characteristics in a baseline questionnaire. Histopathologic variables were obtained from pathology reports. Of 3932 recorded melanomas, data were available and analyzed for 2452 (62%; 1 per patient) with primary in situ (n = 291) or invasive (n = 2161) cutaneous melanoma. Data were analyzed from March 2020 to January 2021.

Main outcomes and measures: Melanoma-specific mortality and all-cause mortality.

Results: A total of 2452 patients were included in the analyses. The median age at diagnosis was 65 years (range, 16-98 years), and 1502 patients (61%) were men. A total of 858 patients (35%) had their melanoma detected during a routine skin check, 1148 (47%) self-detected their melanoma, 293 (12%) had their melanoma discovered incidentally when checking another skin lesion, and 153 (6%) reported "other" presentation. Routine skin-check detection of invasive melanomas was associated with 59% lower melanoma-specific mortality (subhazard ratio, 0.41; 95% CI, 0.28-0.60; P < .001) and 36% lower all-cause mortality (hazard ratio, 0.64; 95% CI, 0.54-0.76; P < .001), adjusted for age and sex, compared with patient-detected melanomas. After adjusting for prognostic factors including ulceration and mitotic rate, the associations were 0.68 (95% CI, 0.44-1.03; P = .13), and 0.75 (95% CI, 0.63-0.90; P = .006), respectively. Factors associated with higher odds of routine skin-check melanoma detection included being male (female vs male, odds ratio [OR], 0.73; 95% CI, 0.60-0.89; P = .003), having previous melanoma (vs none, OR, 2.36; 95% CI, 1.77-3.15; P < .001), having many moles (vs not, OR, 1.39; 95% CI, 1.10-1.77; P = .02), being 50 years or older (eg, 50-59 years vs <40 years, OR, 2.89; 95% CI, 1.92-4.34; P < .001), and living in nonremote areas (eg, remote or very remote vs major cities, OR, 0.23; 95% CI, 0.05-1.04; P = .003).

Conclusions and relevance: In this cohort study, melanomas diagnosed through routine skin checks were associated with significantly lower all-cause mortality, but not melanoma-specific mortality, after adjustment for patient, sociodemographic, and clinicopathologic factors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Soyer reported receiving fees from MoleMap NZ Limited; serving as a medical consultant, minor shareholder, and receiving nonfinancial support from Canfield Scientific Medical; being a shareholder of E-Derm Consult GmbH; receiving medical reporting and consultant fees from Revenio Research OY Medical, and acting as a medical advisor for First Derm Medical outside the submitted work. Dr Scolyer reported receiving fees for professional services from Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc, Bristol Myers Squibb, Myriad Genetics, and GlaxoSmithKline; being a shareholder of MoleMap NZ Limited and E-Derm Consult GmbH; undertaking regular teledermatological reporting for MoleMap NZ Limited and E-Derm Consult; being a medical consultant for Canfield Scientific Inc and Revenio Research Oy; and being a medical advisor for First Derm. Dr Fernandez Peñas reported having these relationships related to inflammatory skin disease (psoriasis, eczema, etc): advisory board participant for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Roche, Merck Sharp & Dohme, Janssen, Novartis, Sanofi, Leo Pharma, Bristol Myers Squibb, and Pfizer; participant in clinical trials for AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Galderma, Eli Lilly and Company, Janssen, Novartis, Oncosec, Pfizer, UCB, Regeneron, and Sun Pharma; and educational lecturer and recipient of honoraria for AbbVie, Amgen, Eli Lilly and Company, Galderma, Janssen, Merck Sharp & Dohme, Merck, Novartis, Pfizer, Roche, Sanofi, and Schering Plough outside the submitted work. Dr Menzies reported receiving personal fees from SciBase AB and from MoleMap NZ Limited outside the submitted work. Dr Chakera reported receiving personal fees as an educational advisor for Sanofi and Merck and receiving grants from Innovation Fund Denmark and the Danish Cancer Society outside the submitted work. Dr Thompson reported receiving honoraria from Bristol Myers Squibb Australia and Merck Sharp & Dohme Australia for advisory board participation; honoraria from GlaxoSmithKline; honoraria and travel support from Provectus; and nonfinancial support from Novartis for meeting attendance outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Subhazard and Hazard Ratios for Mortality Associated With Different Modes of Detection of Invasive Melanoma
Subhazard ratios for melanoma-specific mortality (A) and hazard ratios for all-cause mortality (B). Minimally adjusted analyses were adjusted for age (continuous) and sex. Multivariable-adjusted model 1 was further adjusted for previous melanoma, family history, moles, socioeconomic status, residential remoteness, anatomic site, and melanoma subtype; and multivariable-adjusted model 2 was adjusted for these variables plus ulceration and mitotic rate.

Comment in

  • Melanoma Screening-Time for a Reset?
    Halpern AC, Marchetti MA. Halpern AC, et al. JAMA Dermatol. 2021 Dec 1;157(12):1409-1411. doi: 10.1001/jamadermatol.2021.3883. JAMA Dermatol. 2021. PMID: 34730779 No abstract available.

References

    1. Gordon L, Youl PH, Elwood M, et al. . Diagnosis and management costs of suspicious skin lesions from a population-based melanoma screening programme. J Med Screen. 2007;14(2):98-102. doi:10.1258/096914107781261963 - DOI - PubMed
    1. Elliott TM, Whiteman DC, Olsen CM, Gordon LG. Estimated healthcare costs of melanoma in Australia over 3 years post-diagnosis. Appl Health Econ Health Policy. 2017;15(6):805-816. doi:10.1007/s40258-017-0341-y - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 - DOI - PubMed
    1. Gershenwald JE, Scolyer RA, Hess KR, et al. ; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform . Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. doi:10.3322/caac.21409 - DOI - PMC - PubMed
    1. Weinstock MA. Reducing death from melanoma and standards of evidence. J Invest Dermatol. 2012;132(5):1311-1312. doi:10.1038/jid.2012.57 - DOI - PubMed

Publication types